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Abstract
Endometrial cancer is the most common gynaecologic malignancy in developed countries and its incidence is
increasing. First-level treatment, if no contraindicated, is based on surgery. Pre-operative imaging is needed for
evaluation of local extent and detection of distant metastases in order to guide treatment planning. Radiological
evaluation, based on transvaginal ultrasound, MR and CT, can make the difference in disease management, paying
special attention to assessment of entity of myometrial invasion, cervical stromal extension, and assessment of
lymph nodal involvement and distant metastases.
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Background
Endometrial cancer (EC) is the most common gynaeco-
logic malignancy in developed countries and its inci-
dence is increasing. It usually arises in post-menopausal
women although 20–25% of ECs are diagnosed before
menopause [1]. Multiple risk factors are involved in the
development of EC including obesity, unopposed
oestrogen, early menarche and late menopause.
EC is traditionally classified into two major types (I and
II). Type I tumours (G1-G2 endometrioid adenocarcin-
omas) account for about 80% of endometrial carcinomas,
have a favourable prognosis and are oestrogen-responsive.
Type II tumours account for 10–20% of EC, include high
grade endometrioid tumours, and non-endometrioid
tumours (serous, clear-cell, mucinous, squamous, transi-
tional cell, mesonephric, carcinosarcoma, and undifferen-
tiated), have a poor prognosis and are not clearly
associated with oestrogen stimulation [2].
Staging of EC is based on the FIGO (International
Federation of Gynecology and Obstetrics) staging system
[3] and on TNM categories, which refer to surgical re-
sults. The standard of care for early stage EC patients
with a good performance status and resectable tumour
has been based on surgical removal of uterus and adnexa
+/− pelvic and lombo-aortic lymphadenectomy.
Pre-operative imaging by US, MR and CT has to specif-
ically focus on evaluation of local extent (myometrial
and cervical invasion), and detection of nodal and dis-
tant metastases, in order to assess prognosis and to help
treatment planning.
Main text
Novelties in treatment planning
In 2009 the FIGO staging of EC has been updated, and
FIGO stage Ia and Ib have been merged, because it has
been demonstrated that the prognosis for tumor con-
fined to endometrium or tumor invading the inner half
of the myometrium was comparable [3], thus reducing
the subgroups of stage I to Ia (EC confined to endomet-
rium or invading the inner half of the myometrium) and
Ib (EC invading the outer half of the myometrium).
Furthermore, it has become more and more evident
that prognosis of EC patients depends on multiple differ-
ent factors, most of which not included in the FIGO sta-
ging, such as histological type and grade, age of the
patient, size of the tumour, lymphovascular spaces inva-
sion. Therefore, on one hand many multicentric trials
and society guidelines have attempted to include
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multiple prognostic factors in classification of EC [4]; on
the other hand, recent advances in molecular classifica-
tion of EC by histology has raised the evidence that dif-
ferent outcomes may be related to different expression
of specific mutations and alterations, such as TP53,
PI3K, KRAS, ERBB, FGFR and others [4].
Additionally, there has been a long debate about per-
formance of lymphadenctomy. Indeed, lymph nodal in-
volvement is the most common form of extrauterine
disease spread, related to deep invasion (> 50%) of the
myometrium, grade (G3) or non-endometrioid histolo-
gies [5], and is the strongest predictor of recurrence.
After conflicting results, such as those of two random-
ized trials, showing no therapeutic benefit of lympadect-
omy [6, 7], and a retrospective study showing a better
overall survival rate in intermediate and high-risk EC pa-
tients who underwent systematic lymphadenectomy [8],
sentinel lymph node mapping has been proposed as sur-
gical technique to assess lymph nodal status. This repre-
sents an innovative technique to identify lymph node
metastases, while reducing the surgical morbidity (lym-
phoedema, lymphocysts) associated with systematic
lymphadenectomy [9]. It has to be noted that some cen-
tres, especially in the US, thanking also the advent of the
sentinel node mapping during surgery, do not perform
routinely MR for pre-operative staging. However, MRI is
specifically recommended during the initial workup of
EC patients, in the US as well as in Europe, to establish
the origin of a tumor (endocervical or endometrial), as
well as when planning a fertility-sparing treatment, in
order to confirm the initial stage by excluding myome-
trial invasion, as well as adnexal or pelvic nodes involve-
ment [2, 9].
Finally, minimally invasive surgery, including robotic
assisted surgery, has been introduced, as associated with
significantly fewer moderate-to-severe postoperative ad-
verse events (14% versus 21%) and a lower frequency of
hospitalisations > 2 days (52% versus 94%) than laparot-
omy [2, 10]. For surgical planning, an important factor
not significantly changed overtime, is cervical stromal
invasion, that may require radical hysterectomy instead
of total hysterectomy (performed in patients with tu-
mours confined within the uterus [11]), which may rep-
resent a helpful information for planning operating time,
especially with minimally invasive techniques.
Novelties in imaging evaluation
The most common initial symptom (75%) of EC in post-
menopausal women is abnormal uterine bleeding, and
this allows the possibility of making an early diagnosis.
Gynaecological examination is usually completed by
transvaginal ultrasound (TVUS), which usually repre-
sents the first imaging evaluation. TVUS is performed
with a dedicated vaginal probe using high frequencies
and a small field of view, which allows good local evalu-
ation. Many studies indicate an endometrial thickness of
5mm as the normal cut-off value in post-menopausal
women [4], but in the presence of bleeding this cut-off
value may be lowered to 3mm [12]. Three-dimensional
TVUS (3D-TVUS) is a novel technique which acquires US
images that may be reconstructed in any desired plane, to
better depict myometrial invasion in the uterine corners
[13]. However, results are equivocal and 3D-TVUS has
not yet proved superior to conventional 2D-TVUS in the
assessment of myometrial involvement and identification
of cervical infiltration [14]. When TVUS is performed in a
referral centre, it is not always requested to perform an
additional imaging examination for evaluation of local ex-
tent, such as MR, and the patient may complete the
pre-operative staging with a CT scan.
MR with paramagnetic contrast agent is considered an
accurate imaging technique for local staging, because
the tumoral tissue, the endometrium and the myome-
trium show different MR signals, especially on T2w im-
ages. However, since these differences may be less
evident in post-menopausal women, acquisition of dy-
namic images after injection of contrast medium is rec-
ommended [15]. The European Society of Uro-genital
Radiology has suggested in 2009 a dedicated MR proto-
col for accurate local staging of endometrial carcinoma
[15], based on T2-w acquisitions in three orthogonal
planes oriented to the uterine cavity (sagittal, axial ob-
lique and coronal oblique), with additional sequences
oriented to the long axis of the endocervical canal. The
slice thickness recommended is 3–4 mm with a small
FOV of 20–25 cm. In order to detect nodal involvement,
coronal T1-w with extended FOV is also suggested. Fi-
nally, para-axial dynamic T1-w after intravenous bolus
injection of a paramagnetic contrast agent is advocated
for optimal evaluation of myometrial invasion.
After publication of the abovementioned guidelines,
many advances in knowledge of EC behaviour and in im-
aging technology have been achieved, with the conse-
quence of some novelties in patient management.
In literature, several articles have been published
about the role of 3 T MR in the preoperative evalu-
ation of depth of myometrial infiltration and accuracy
has been reported equivalent to that of 1.5 T MR
[16]. MR imaging using 3 T equipment, with a higher
Signal-to-Noise Ratio (SNR) than 1.5 T examinations,
may lead to a more advanced temporal and spatial
resolution, although it is also known that at 3 T the
quality of abdominal imaging may be influenced by
some artefacts. In fact, there are some known restric-
tions to the use of a higher magnetic field, such as
an increased T1 relaxation time, a reduced T2 relax-
ation time and a higher magnetic susceptibility and
chemical shift artifacts [17].
Rizzo et al. Cancer Imaging           (2018) 18:45 Page 2 of 12
At the time of publication of these guidelines,
Diffusion-Weighted Imaging (DWI) was indicated as a
promising tool in assessing gynecologic cancers, provid-
ing information on tumour cellularity and microenviron-
ment. After some years of experience, DWI is currently
widely used as an adjunct to T2w and dynamic imaging
in routine clinical practice [18]. Indeed, it is now well
known that DWI is a helpful tool in detecting EC when
endometrial biopsy is technically impossible, due to cer-
vical stenosis, as well as when histopathologic results are
inconclusive, because ADC values are significantly lower
in cancer than normal endometrium or benign polyps
[19, 20]. A recent systematic review and meta-analysis
evaluating pre-operative staging of myometrial invasion
in EC patients has shown that in different studies pub-
lished between 2008 and 2013, DWI sequences were
performed with different high b-values ranging between
500 and 1000, where the highest b-value (b = 1000) was
mainly on 3 Tesla machines [21–23], whereas on 1.5
Tesla machines the highest b-value used was more fre-
quently b = 800 [24, 25], with few exceptions [26].
It is also under consideration if the combination of
T2w images and DWI may be superior to dynamic
contrast-enhanced MR. Indeed, a meta-analysis includ-
ing 9 studies (442 patients) comparing the diagnostic ac-
curacy of dynamic contrast-enchanced (DCE) MR
imaging and DWI to predict deep myometrial invasion,
showed no differencies in pooled sensitivities and speci-
ficities of the two sequences [27]. However, in a more re-
cent meta-analysis including 15 studies and 849 patients,
the specificity of T2w images plus DWI was superior to
that of DCE MR imaging [28].
Evidences suggest that fusion T2-DWI imaging at 3-T
has an 88% accuracy in the assessment of the depth of
myometrial invasion, with a similar diagnostic perform-
ance as DCE MRI [29]. In addition, the use of a reduced
FOV for DWI imaging may improve the local staging ac-
curacy of MRI in the assessment of the depth of myome-
trial invasion; in particular for patients with coexisting
adenomyosis, it can be a helpful alternative diagnostic
tool to 3D DCE MRI [30]. Field-of-view (FOV) opti-
mized and constrained undistorted single shot (FOCUS)
is a new sequence clinically applied by using a two di-
mensional spectral spatial excitation radiofrequency
pulse, which limits the signal to a small FOV, thus ex-
cluding possible sources of artifacts that are outside the
region of interest [30]. This may avoid local field homo-
geneity conditions, and minimize off-resonance artifacts
due to B0 inhomogeneity, susceptibility gradients, eddy
currents, and chemical shift [31, 32]. Reduced FOV DW
imaging with high spatial resolution may enhance the le-
sion detection, and the evaluation of tumor extent in
endometrial cancer. Indeed, severe geometric distortion
at air-tissue interfaces around the uterus, ovaries and
rectum, can be minimized on reduced FOV DW im-
aging. However, since the small FOV may be a limit for
the detection of lymph node metastases, peritoneal dis-
semination and/or bone metastases, reduced FOV DW
imaging is considered as an additional sequence to the
traditional large FOV DW sequence, for the evaluation
of local tumor extent [30].
Bhosale et al. reported the feasibility of reduced FOV
DW imaging in the assessment of myometrial invasion
in patients with clinical FIGO stage I endometrial can-
cer. In this study the authors demonstrated the feasibil-
ity of IVIM parameters as imaging markers of MSI
status (Micro-Satellite Instability), defined as a germline
mutation of mismatch repair system (DNA polymerase)
that leads to a higher risk to develop EC. Furthermore,
compared with T2-weighted imaging plus DCE MR, re-
duced FOV DW imaging yielded greater specificity and
accuracy for deep myometrial invasion determined by
one reader, and greater the sensitivity for deep myome-
trial invasion determined by another reader [31].
Recently there has been a growing need for a
non-invasive imaging method for the accurate diagnosis
and differentiation of endometrial malignancy. With this
regard, it has been demonstrated that DW signal and
ADC values can be influenced not only by molecular
proton diffusion, but also by microcirculation or blood
perfusion. Some Authors have reported the feasibility to
study the tissue characteristics of endometrial cancer
using IVIM model at 3 T and to assess their diagnostic
potential [32]. In this study, ADC values derived from a
mono-exponential model of DWI containing perfusion
effect were demonstrated to limit the reliability of ADC
in characterizing lesions [33]. The IntraVoxel Incoherent
Motion (IVIM) has been used to estimate perfusion in
tissues, as blood flow in randomly oriented capillaries
mimics a pseudo-diffusion process. By using IVIM-based
perfusion MRI, microcirculation or perfusion effects can
be distinguished from true tissue diffusion, when using a
sufficient b value sampling and bi-exponential curve fit
analysis with the intravoxel incoherent motion (IVIM)
model [34]. IVIM MRI can be considered as an exten-
sion of DWI that enables the simultaneous acquisition
of both microcirculatory and diffusivity information. The
capillary network lacks the spatial orientation and the
molecular motion within the microcirculation; this can
be viewed as “pseudo-diffusion”. This pseudo-diffusion is
significant at the lower b-value range (< 200 s/mm2) and
the following two quantitative perfusion parameters can
be derived from analysing the steeper part of the diffu-
sional signal decay curve: the fractional perfusion related
to the microcirculation, and the pseudo-diffusion coeffi-
cient that measures the incoherent perfusion-related dif-
fusion within the microcirculation. The primary
advantage of IVIM is that it enables the simultaneous
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acquisition of diffusion and perfusion parameters and
therefore can provide both measurements without the
requirement of a further co-registration processing
step [18, 35]. The perfusion characteristic differs be-
tween tissue types in the female pelvis: tumoral perfu-
sion affects the sensitivity to chemo-radiotherapy,
whereas altered vasculatures and variable levels of
aniogenic factors within gynecological disease are
thought to determine therapeutic success following
interventional therapy. Endometrial cancer has low
perfusion and high diffusion IVIM characteristics
with promising potential for early non-invasive diag-
nosis, hence proving potentially useful for tissue
differentiation.
CT has a low sensitivity (83%) and specificity (42%) in
detecting and evaluating myometrial involvement, as
well as in assessing cervical stromal invasion [36]. How-
ever, dual-energy CT evaluation of deep myometrial
Fig. 1 A 52-year-old woman with endometrioid adenocarcinoma (stage IA). Transvaginal ultrasound shows the endometrial cancer invading <
50% of the myometrium
Fig. 2 A 51-year-old woman with endometrioid adenocarcinoma invading < 50% of the myometrium. Sagittal T2-w MRI (a) shows an
intermediate-signal intensity tumour with disruption of the low signal junctional zone but the extent of myometrial invasion is unclear.
Corresponding axial DWI image (b) shows an area of high signal intensity within the endometrial tumour invading only the inner
myometrium (arrow)
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invasion has been suggested [37], and CT is widely rec-
ognized as helpful in assessing distant metastases.
PET/CT is more sensitive than CT or MR imaging for
detection of nodal metastases [38, 39]. Furthermore, in
patients for whom biopsy demonstrates high-risk hist-
ology, PET/CT may be used to identify unsuspected dis-
tant disease that would obviate the morbidity of a
staging operation. Two meta-analyses have indeed
shown that PET/CT is highly sensitive and specific for
distant nodal metastasis [40–42], although a significant
percentage of lymph nodes still go undetected by PET/
CT. In a direct comparison of MR imaging and PET/CT
for initial staging, PET/CT was found superior for detec-
tion of metastatic lymph nodes (sensitivity 70% for PET/
CT vs 34% for MR imaging) [38].
Recently introduced PET/MR scanners acquire MR
and PET data either simultaneously or sequentially. In
gynaecologic cancer patients, 18F-FDG PET/MR proto-
cols are intended to provide a sole examination to solve
the problems of treatment planning, as well as for evalu-
ation of prognosis and surveillance. Indeed, in simultan-
eous PET/MR scanners, during the PET acquisition,
whole-body Dixon images, the anatomically descriptive
half-Fourier acquisition single-shot turbo spin-echo im-
ages, and fluid-sensitive inversion recovery images and
DWI are co-acquired; these acquisitions are then com-
pleted for local staging by a dedicated pelvic MR includ-
ing dynamic intravenous gadolinium administration. MR
imaging and PET are complementary in the initial sta-
ging of endometrial cancer because MR is more accurate
Fig. 3 A 66-year-old woman with endometrioid adenocarcinoma, grade 3. Sagittal T2-weighted image shows an intermediate-signal intensity
endometrial tumour invading > 50% of the myometrium (a), with disruption of the low T2 signal junctional zone (white asterisk) and preservation
of the low signal band of the outer myometrium (black arrowhead). Sagittal post contrast CT (b) in the same patient, performed for evaluation of
distant metastases, does not discriminate the extent of myometrial infiltration
Fig. 4 A 75-year-old woman with endometrioid carcinoma. Paracoronal post-gadoliunium T1-w subtracted dynamic images at 0 s (a), 60s (b) and
90s (c) help the evaluation of deep myometrial invasion in a post-menopausal patient
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for evaluation of local extent of the tumour, whereas
PET is more accurate for distant metastases. Lesions de-
tected on PET or DWI can be precisely localized and char-
acterized on the conventional MR sequences, thereby
allowing for improved sensitivity without a loss of specifi-
city. In a direct comparison of fused PET/MR imaging, MR
imaging, and PET/CT data, PET/MR imaging and MR im-
aging alone were both more accurate for local staging of
endometrial cancer (T-stage accuracy 80% for PET/MR im-
aging or MR imaging alone vs 60% for PET/CT) [39].
For association with prognosis after therapy, both PET
and MR imaging features of endometrial cancer have
been evaluated [40]. The preoperative maximum SUV
has been correlated with the presence of high-risk or
low-risk disease after surgical staging [43]. Accordingly,
tumors with high-risk features, such as deep myometrial
invasion, cervical invasion, lymphovascular space in-
volvement, and lymph node metastases, showed high
maximum SUV and low minimum ADC [44].
Imaging keypoints according to stage
Stage I
FIGO stage IA include tumours involving only the endo-
metrium or < 50% of the myometrium. Stage IB repre-
sents > 50% invasion of the myometrium, which is a
marker of potential lymphovascular space invasion and,
therefore, nodal metastases.
At TVUS, myometrial invasion appears as an
iso-hyperechoic tissue compared to the surrounding myo-
metrium. Although myometrial invasion can often be
well-appreciated, sometimes it can only be presumed ac-
cording to an irregular aspect of the endomyometrial junc-
tion (Fig. 1) [45]. Both objective and subjective methods
have been used to assess the depth of myometrial invasion.
Objective assessment is performed by means of Gordon’s
and Karlsson’s approaches. According to Gordon, deep
myometrial invasion is defined as the ratio between max-
imum tumour depth and total myometrial thickness,
whereas for Karlsson a > =50% ratio between the anteropos-
terior diameter of the lesion and the anteroposterior diam-
eter of the uterus defines deep myometrial invasion [46, 47].
Subjective assessment of myometrial invasion (sensi-
tivity 77%, specificity 81%) may be as good as or better
than any objective measurement technique. Indeed, fix-
ing the sensitivity at the same level as that of subjective
evaluation (i.e. 77%), all objective measurement tech-
niques (except minimal tumour-free margin/uterine AP
diameter ratio) showed a significantly lower specificity
[48]. MRI discriminates the degree of myometrial infil-
tration with a sensitivity of 87% [49]. In order to meas-
ure the depth of myometrial infiltration on MR images,
a line must be drawn along the expected inner edge of the
Fig. 5 A 67-year-old patient with endometrioid carcinoma of the
uterus, grade 2. Axial T2-weighted-DWI fused image shows an
overlap of high DWI signal intensity and thicker uterine wall in the
right side of the uterus. This makes the detection of tumour depth
easier and more confident
Fig. 6 Images of a 56-year-old woman with biopsy proved prostate cancer: multiparametric study: T2WI (a). FOCUS DWI images of b = 1000 s/
mm2 (b and c). Perfusion map T2WI on sagittal plane (d) shows endometrial lesion confined to the endometrial cavity. FOCUS DWI images show
tumor lesion in higher spatial resolution with a definite clear border, less artifacts, and image blurring
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myometrium (corresponding to the endometrium–myo-
metrium junction) on axial oblique images acquired per-
pendicular to the endometrium; then, 2 measures have to
be taken: one representing the thickness of the entire
myometrium; the other measuring the maximum tumor
extent within the myometrium. The ratio of these 2 mea-
sures represent the percentage of myometrial invasion
[50]. In stage IA, either the low T2 signal of the junctional
zone, representing the limit between endometrium and
myometrium, is normal and a complete sub-endometrial
enhancement on T1 contrast imaging is present, or there
is a disruption of the low T2-w signal junctional zone with
< 50% invasion of the myometrium (Fig. 2).
In stage IB tumours, disruption or irregularity of the
low T2-w signal junctional zone and/or of
sub-endometrial enhancement in post-contrast T1 im-
ages with myometrial invasion > 50% can be demon-
strated (Fig. 3). Dynamic axial T1 images after
intravenous injection of paramagnetic contrast agent
with a timing between 90 and 150 s are helpful for an
optimal evaluation of myometrial invasion, especially in
post-menopausal women [51, 52] (Fig. 4).
Fig. 7 A 61-year-old women with endometrioid adenocarcinoma, grade 2. TVUS shows an exophytic isoechoic lesion extending to the cervix, as
confirmed by post-surgical pathology
Fig. 8 A 54-year-old women with EC. Sagittal (a) and axial (b) T2-w images show infiltration of the cervical stroma, without extension to the
parametria, staging this tumour as II
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As mentioned above, DWI sequences could help radi-
ologists to assess myometrial invasion, alone or in com-
bination with T2w images (Figs. 5 and 6) [29]. This
might be particularly helpful in cases of tumours extend-
ing to the cornua, myometrial compression from a
polypoid tumor, leiomyomas, or adenomyosis, where
anatomic details on morphologic images could be con-
fusing, or in patients with relative contraindications to
gadolinium-based contrast agents.
Stage II
EC is classified as stage II in case of cervical stromal
invasion, and is associated with a poorer prognosis
due to the higher risk of lymphovascular space inva-
sion. At TVUS, the assessment of cervical invasion
can be difficult as prominent pathologic tissues may
sometimes protrude through the internal uterine ost-
ium into the cervical canal with no infiltration of
the endocervical glandular epithelium, in which case
a slight pressure with the probe may be helpful.
However, iso-hyperechoic endometrial thickening of
the cervical canal may suggest cervical involvement
by endometrial cancer which may extend deeper into
the cervical stroma (Fig. 7). The distance from the
outer cervical os to the lower tumour margin is the
only parameter that might have the potential to pre-
dict cervical invasion. It showed a non-significant
higher sensitivity than did subjective evaluation (73%
vs 54%, P = 0.06), but a significantly lower specificity
(63% vs 93%, P < 0.001) [47]. Stages IIA and IIB are
hardly distinguished by TVUS. Nevertheless, both
groups of patients undergo radical hysterectomy,
with bilateral salpingo-oophorectomy and systematic
pelvic lymphadenectomy with or without para-aortic
lymphadenectomy [2, 44, 53, 54].
MRI discriminates the degree of infiltration of the cer-
vical stroma and vaginal walls with a sensitivity of 80%
and, in addition, it can help in the assessment of para-
metrial infiltration [49].
In stage IIA, MR shows widening of the internal os
and on T2-w images the endocervical canal is occupied
by hyper/isointense tissue, with an intact low signal of
the cervical stroma. If the hypointense stromal ring is
disrupted, the tumour is staged as IIB (Fig. 8).
Fig. 9 A 67-year-old woman with EC stage IIIA. MR sagittal T2-w
image depicting the endometrial lesion of the posterior uterine wall
extending to the internal orifice without cervical involvement. There is
a disruption of the junctional zone (arrowhead) indicating myometrial
invasion, and disruption of the hypointense line contouring the
myometrium on the outer side of the uterus (arrow), indicating serosal
invasion. Collaterally there is a submucosal leiomyoma (asterisk)
Fig. 10 A 54-year-old EC patient with deep myometrial infiltration and serosal involvement. Coronal (a) and sagittal (b) MR images show a small
mass in the right ovary (arrows) with solid components of the same signal intensity as the EC, representing ovarian involvement
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The use of dynamic contrast MRI could help distin-
guish between stromal invasion and polypoid tumour
protruding into the endocervix [18]. If delayed phase
images show tumour protrusion and normal enhance-
ment of the cervical mucosa, stromal invasion can be
excluded [55].
Stage III
Stage III indicates local tumour spread beyond the
uterus but not outside the true pelvis. The subset IIIA
shows the invasion of serosa with a disruption of the
contour of the outer myometrium or adnexa involve-
ment. The subset IIIB shows direct parametrium or vagi-
nal infiltration. Stage IIIC indicates nodal involvement
and is subdivided into pelvic (stage IIIC1) and
para-aortic (stage IIIC2) nodal involvement.
TVUS can be used to diagnose metastatic disease to
the ovaries with a sensitivity and specificity of subjective
evaluation of grey-scale and Doppler ultrasound findings
of 84–91% and 94–100%, respectively, when used by ex-
perienced ultrasound examiners with regard to making a
specific diagnosis of adnexal masses [56].
In stage IIIA, MR shows invasion of the serosa with
disruption of low T2-w signal uterine serosa (Fig. 9)
and/or adnexa (Fig. 10) with irregularity to the uterine
contour. In stage IIIB, MR shows thickening of the vagi-
nal wall and a high T2-w signal tumour infiltrating the
low signal vaginal wall, or irregular intensity of the para-
metria (Fig. 11), respectively. Also in these cases, DWI
Fig. 11 A 57-year-old woman with EC stage IIIB. Para-axial T2-w MR image (a) shows the endometrial carcinoma extending to the left parametrium
(arrow). The tumour infiltrates the cervix through the internal uterine ostium leading to a retrodilation of the cavity which appears occupied by fluid
(asterisk). In the same patient, the axial CT image shows the mass invading the left parametrium (b); collaterally there is a centimetric leiomyoma of
the left wall of the uterus
Fig. 12 A 46-year-old woman with EC grade 3. TVUS image (a) shows an endometrial mass of 4.79 cm (measure in yellow) invading < 50% of the
myometrium. Despite a superficial myometrial invasion, CT images at staging (b) showed pelvic and lombo-aortic lymphoadenopathies (arrow),
that bwere confirmed at surgery
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improves the depiction of extrauterine metastatic de-
posits into the parametrium or vagina [11].
In stage IIIC, MR shows pelvic or para-aortic lymph-
adenopathies (Fig. 12). Further studies of 1.5-T MR im-
ages reported conflicting results [57, 58]. Lin et al.
reported good results in differentiating metastatic and
benign lymph nodes with 3 T-MRI, combining ADC
values, relative ADC values, and size criteria [29].
Stage IV
Stage IV disease represents direct full thickness invasion
of the bladder or rectal mucosa (stage IVA) or the pres-
ence of distant metastases (stage IVB). On T2-weighted
images, extension of tumor directly into the normally
hyperintense vescical or rectal mucosa is indicative of
endometrial tumor invasion, however, the sole disrup-
tion of the hypointense muscularis layer does not indi-
cate stage IV disease because it cannot be visualized at
subsequent cystoscopy or sigmoidoscopy. Similarly, bul-
lous edema, which appears as thickening of the
high-signal-intensity mucosal layer, is not indicative of
mucosal invasion. In stage IVA, MR may clearly depict
disruption of the low T2-w signal of the bladder or rec-
tal wall through the whole thickness of the wall, and/or
intraluminal bladder mass (Fig. 13); whereas in stage
IVB, malignant ascites with peritoneal deposits,
para-aortic lymphadenopathy above the renal vessels or
inguinal node metastases can be demonstrated.
Conclusion
In conclusion, EC is the most common gynaecologic
malignancy in developed countries. As treatment plan-
ning has been changing over time, pre-operating im-
aging evaluation has to follow novelties in treatment, in
order to offer the appropriate information to surgeons
and/or oncologists for optimal management of patients.
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